Progressive pulmonary fibrosis (PPF) is a life-threatening, progressive lung condition, causing a continuous decline in lung function.1,2 -- Affecting up to 100,000 people in the U.S. and up to 5.6 ...

Boehringer Ingelheim’s JASCAYD® (nerandomilast) tablets has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of progressive pulmonary fibrosis (PPF) in adults.5 ...

Just two months after reviving its prowess in the idiopathic pulmonary fibrosis (IPF) treatment area with rare lung disease med Jascayd, Boehringer Ingelheim is already unlocking another patient po | ...

The Prognostic Lung Fibrosis Consortium , a collaborative consortium advancing biomarker tools for pulmonary fibrosis (PF) ...

Exciting news for those affected by progressive pulmonary fibrosis (PPF): The US FDA has granted approval for Jascayd (nerandomilast). This groundbreaking medication goes beyond merely alleviating ...

When lungs fail to maintain vital oxygen and carbon dioxide levels, respiratory failure occurs, posing a serious threat. This condition, categorized as Type I (low oxygen) or Type II (high carbon ...

Trevi Therapeutics (TRVI) is initiated with a "Buy" rating, driven by its lead asset Haduvio’s advancement toward phase 3 testing for chronic cough in IPF. Company's Haduvio demonstrated statistically ...

Insmed sinks nearly 20% after Brinsupri failed a phase IIb sinus study, while the company adds a new monoclonal antibody asset to expand its pipeline.

The doctor’s words hit Paul Rivera hard. This wasn’t just a cold; he had pulmonary fibrosis, a progressive condition where the lungs become scarred and unable to send oxygen to the brain and heart.

Those who discontinued therapies tended to have higher lung function at the start of ETI and were less likely to be infected with Pseudomonas aeruginosa, a common CF-related lung infection. Because ...

GRI Bio, Inc. (NASDAQ: GRI) on Wednesday shared topline data from the Phase 2a GRI-0621-IPF-02 trial evaluating GRI-0621 for idiopathic pulmonary fibrosis. IPF is a chronic, progressive lung disease ...